Nectin-4 PET/CT imaging to differentiate renal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study evaluates safety, biodistribution, and imaging features of 18F-N230A PET/CT in patients with suspected or confirmed renal tumors who are scheduled for biopsy or surgery. Participants undergo 18F-N230A PET/CT and standard 18F-FDG PET/CT, with imaging results compared to pathology as the reference standard. The goal is to determine whether 18F-N230A PET/CT provides clearer differentiation between tumor types and adds value to preoperative planning. Data on imaging quantification and diagnostic performance will be analyzed. The study is conducted at Peking University First Hospital and is limited to adults.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants aged ≥18 years.
* Patients with suspected or confirmed renal tumors who are scheduled for pathological examination by biopsy or surgical resection within 2 months.
* Patients who can understand the study procedures and voluntarily provide written informed consent.
* Patients who can cooperate with PET/CT imaging procedures.

Exclusion Criteria:

* Patients with severe abnormalities in liver function, renal function, or blood cell counts.
* Patients unable to understand the study procedures or unable to cooperate with imaging examinations.
* Patients with a history of other malignant tumors.
* Patients considered unsuitable for participation by the investigator.

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jianhua Zhang
• Email: zjhjn820@163.com
• Phone: 86-10-83572791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Weight-loss programs to slow kidney cancer progression in small renal masses on active surveillance

  This study tests two weight-loss approaches, daily calorie restriction and 5:2 intermittent fasting, to see if they help people with small kidney tumors on active surveillance lose weight and potentially slow cancer progression.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07714018

• Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD

  This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07657325

• Safety and tolerability test of anti-CD70 T-cell therapy in advanced RCC

  This study tests a CD70-targeted CAR-T cell therapy in adults with advanced or metastatic renal cell carcinoma to see if it is safe and tolerable and to identify a usable dose for future studies.

  Recruiting Phase 1 Hrain Biotechnology Co., Ltd. · Shanghai · NCT07647744

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Laparoscopic versus open kidney removal: comparing outcomes and costs

  This trial will test whether laparoscopic (keyhole) kidney removal or open surgery gives better outcomes and lower costs for people needing a nephrectomy for a nonfunctioning kidney or localized kidney cancer.

  Recruiting Menoufia University · Shibīn al Kawm, Shebin Elkom · NCT07461090

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.